Corcept Therapeutics Incorporated
CORT
Rang in Aktien
#1700
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Aktienkurs
$116.87
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$12.63B
Veränderung (1 Tag)
4.25%
Veränderung (1 Jahr)
55.01%
Land
US
Handel Corcept Therapeutics Incorporated (CORT)
Kategorie
Healthcare
Umsatz von Corcept Therapeutics Incorporated (CORT)
Umsatz im Jun 2026 TTM: $830.81M
Laut den aktuellen Finanzberichten von Corcept Therapeutics Incorporated beträgt der derzeitige Umsatz des Unternehmens (TTM) $830.81M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $482.38M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $401.86M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Corcept Therapeutics Incorporated von 2001 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $830.81M | 23.08% |
| 2024 | $675.04M | 39.94% |
| 2023 | $482.38M | 20.04% |
| 2022 | $401.86M | 9.80% |
| 2021 | $365.98M | 3.42% |
| 2020 | $353.87M | 15.46% |
| 2019 | $306.49M | 21.99% |
| 2018 | $251.25M | 57.82% |
| 2017 | $159.20M | 95.77% |
| 2016 | $81.32M | 61.72% |
| 2015 | $50.29M | 89.39% |
| 2014 | $26.55M | 156.36% |
| 2013 | $10.36M | 213.18% |
| 2012 | $3.31M | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | -100.00% |
| 2009 | $29.00K | -86.12% |
| 2008 | $209.00K | -56.64% |
| 2007 | $482.00K | 63.95% |
| 2006 | $294.00K | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $2.54B | 205.24% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $4.88B | 487.88% |
HK
|
